Duke logo

UM1 10015 Trametinib (Epithelioid Hemangioendothelioma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study is to test any good and bad effects of the study drug called trametinib in people with epithelioid hemangioendothelioma (EHE).

What is the Condition Being Studied?

Epithelioid hemangioendothelioma (EHE)

Who Can Participate in the Study?

Adult patients with epithelioid hemangioendothelioma (also called EHE), a rare type of cancer that is thought to develop from blood vessel cells.

Age Group
Adults

What is Involved?

If you join this study you will get the study drug trametinib.

You will take a pill every day of each treatment cycle. A cycle is 28 days (4 weeks of treatment).

This study has two parts. Your doctor will inform you if you are in the first or second group.
-- Group 1 consists of the first 13 participants treated with trametinib.
-- If the cancer shrinks by 30% or more in at least 1 of the patients, the study will enroll up to 14 more participants.
-- Group 2: consists of the next 14 participants to receive trametinib.

Study Details

Full Title
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma
Principal Investigator
Medical Oncologist
Protocol Number
IRB:PRO00083588
NCT:NCT03148275
Phase
Phase II
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698